semaglutide weight loss trial Long-Term SELECT Trial: Cuts Cardiovascular Events by 20% beyond Semaglutide 7.2 mg Displays 20.7%

GLP-1 receptor agonists also reduce the three components of MACE, including CV mortality (reduced by 13%), nonfatal stroke (reduced by 16%) and nonfatal myocardial infarction (reduced by 9%, although the level of significance was not reached)

For tirzepatide, 4 days

When Eli Lilly says 21 days at room temperature, that claim is backed by accelerated stability studies and real-time data submitted to the FDA

MedlinePlus Drug Information [6] National Institute of Diabetes and Digestive and Kidney Diseases

Generally speaking, 2 grams per day is considered a safe dosage free from serious side effects

Warmly, Mia from The Gentle Plate Follow us on Facebook